Aphaia Pharma

About Aphaia Pharma

Aphaia Pharma is a clinical‑stage biopharma company focused on restoring endogenous endocrine balance to treat metabolic disorders. Based in Zug, Switzerland, the company develops precision-targeted drug formulations aimed at obesity and related metabolic diseases, with a lead oral glucose formulation intended to activate nutrient-sensing pathways in the distal small intestine. Their programs include Phase 2 trials for obesity and prediabetes to evaluate weight changes and metabolic parameters. Aphaia aims to provide long‑term therapeutic benefits with minimal side effects by reestablishing the body’s natural hormonal responses.